This is excellent - clear path to market , short time frame and potential PRV for a medical counter measure molecule (MCM) which would be valued at $150 mill USD alone on NDA (plus we would get one potentially for ILA-101 for tropical disease).
Animal rule for Gal will allow us to go straight to a pivotal animal trial and bypass the traditional P2/P3 route . I cannot think of ever seeing another ASX company having this opportunity .
Ann: Portfolio expansion achieved with acquisition of Galidesivir, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
20.5¢ |
Change
0.005(2.50%) |
Mkt cap ! $50.68M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 20.5¢ | 19.5¢ | $57.51K | 288.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3076 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.5¢ | 119493 | 2 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| ILA (ASX) Chart |